Viatris beats third quarter 2026 earnings expectations and raises its full-year guidance

Viatris reported third quarter 2026 revenue of $3.75 billion, slightly below expectations, though adjusted EPS of $0.71 exceeded analyst estimates. The company reported a GAAP net loss of $325 million, primarily attributed to tax provisions, but raised its full-year performance outlook across all key metrics due to operational momentum in higher-margin segments.

Key Highlights

• New product revenue generated $115 million during the quarter, with full-year expectations now set at approximately $450 million.
• The company raised its 2026 guidance midpoints for total revenue to $14.8 billion and adjusted EPS to $2.60.
• Total revenue was impacted by approximately $100 million due to supply constraints and remediation at its Nashik facility, which is expected to resume production in early 2027.
• Viatris entered a definitive agreement to acquire Pacira BioSciences for $1.65 billion, a transaction expected to close in late November 2026.